So, TZDs increase adiponectin levels in addition to any weight gain, commonly seen with these drugs and usually associated with reduced adiponectin levels and adverse effects in NAFLD, likely through the induction of adiponectin production and secretion, which counterbalances the increase of body weight induced by TZDs [142]. This evidence concerns the gene ADIPOQ and metabolic dysfunction-associated steatotic liver disease.